LAPLACE 2: Evolocumab effective in reducing LDL associated with statins

There are several patients who do not reach recommended LDL cholesterol despite maximally tolerated doses of statins levels.The Evolocumab is a monoclonal antibody that inhibits protein converting subtilisin / kexin type 9 (PCSK9) showed lowering LDL cholesterol in phase 2 studies.

The objective of this Phase 3 study was to evaluate the safety and efficacy of subcutaneous administration of Evolocumab for 12 weeks in combination with statins in patients with hypercholesterolemia or mixed dyslipidemia and also compare their performance with ezetimibe.1896 patients were randomized to receive the study drug once a month or every two weeks with a placebo controlled group and an ezetimibe group, showing a reduction of between 63 and 75% with Evolocumab relative to placebo. Ezetimibe made a reduction of between 19 and 32% compared with placebo.

Conclusion

The Evolocumab significantly reduces LDL by 10-12 weeks associated with a statin. Both dosage regimens were clinically equivalent and no differences in the safety profile and tolerance between treatment groups.

7_jennifer_robinson
Jennifer G Robinson
2014-03-31

Original title: The Low-density Lipoprotein Cholesterol Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy – 2 Trial: A Phase 3, Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia (LAPLACE-2 Trial).

More articles by this author

CORP-2 Trial: Colchicine effective in reducing the recurrence of pericarditis associated withconventional anti-inflammatory pattern.

Colchicine is effective in treating an acute pericarditis event and initial recurrences;however, there is no conclusive data on its efficacy and safety in the...

Melody

The ducts of the right ventricle to the pulmonary artery are used in approximately 20 % of all patients with congenital defects including tetralogy...

Negative ultrasensitive troponin T values may help discriminate patients with chest pain in the emergency

New laboratory tests can detect minimally elevated  levels few hours before regarding detection methodologies of previous generations.The hypothesis of this study is that patients...

MADIT -CRT: Increased survival with resynchronization therapy plus defibrillator in patients with mild heart failure.

The MADIT -CRT study (Multicenter Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy) had shown that early intervention with cardiac resynchronization therapy plus defibrillator in...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...